NCT02375204: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors |
|
|
| Active, not recruiting | 3 | 420 | Europe, US, RoW | paclitaxel, Taxol, ifosfamide, Ifex®, IFOS, cisplatin, CDDP, pegylated G-CSF, G-CSF, carboplatin, Paraplatin®, CBDCA, etoposide phosphate, VePesid®, Toposar®, VP16, stem cell reinfusion | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment of Cancer - EORTC, Movember Foundation, Institute of Cancer Research (ICR), United Kingdom, Cancer Research UK, UNICANCER, Irish Group CTI | Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma | 06/31 | 06/31 | | |
| Recruiting | 1 | 476 | Europe, US | IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, nivolumab (Opdivo®), Opdivo®, IMADetect® | Immatics US, Inc., Immatics US Inc | Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer | 12/28 | 12/28 | | |
NCT04600206: Existential Distress in Patients With Advanced Cancer and Their Caregivers |
|
|
| Active, not recruiting | N/A | 800 | Europe | Self-report questionnaires | Universitätsklinikum Hamburg-Eppendorf | Neoplasms Malignant, Carcinoma, Palliative Care | 06/24 | 06/24 | | |
